In addition, interlinking metabolic association between T2DM and cancer has been widely reported, suggesting the metabolic pathway mTOR/p70S6K1 and mTOR inhibitors, prescribed to overcome hormone receptor-positive BC resistance to hormone therapy, as emerging therapeutic targets against metastatic BC [22,23,24]. This evidence concerns the gene RPS6KB1 and breast cancer.